title: [Safety and efficacy of human umbilical cord derived-mesenchymal stem cell transplantation for treating patients with HBV-related decompensated cirrhosis].
abstract: OBJECTIVE
  To retrospectively investigate the efficacy of human umbilical cord-derived mesenchymal stem cells (UC-MSC) as clinical treatment for HBV-related decompensated liver cirrhosis (HBV-DLC)•D.
  
  
  METHODS
  Sixty patients with HBV-DLC were given standard medical treatment combined with a 3-month regimen of UC-MSC at a dose of 0.5-1.0×10(6) cells/kg/month. Another group of patients with HBV-DLC (n=120; control group) that was matched (2:1) to the case group by age, sex, diagnosis, and follow-up period was given the standard medical treatment only. We reviewed all patients' data of biochemical tests, imaging examinations, Child-Pugh scores, and adverse reactions. Comparisons of continuous data between the two groups were made by independent-sample t-test, and comparisons of categorical data were made by chi-square test.
  
  
  RESULTS
  Compared with the control group, the group that received the combination UC-MSC treatment showed a significant rise in cholinesterase, globulin and alkaline phosphatase, and reduced Child-Pugh scores during the follow-up period. However, there was no significant difference between the groups of patients for levels of alanine transaminase, total bilirubin, albumin, total cholesterol, or prothrombin activity.
  
  
  CONCLUSIONS
  Addition of the UC-MSC treatment to the standard therapy could help to improve liver function in patients with HBV-DLC.
authors.affiliation: Research Center for Biological Therapy, Beijing 302 Hospital, Beijing 100039, China.
authors.forename: S J
authors.initials: SJ
authors.lastname: Yu
authors.forename: L M
authors.initials: LM
authors.lastname: Chen
authors.forename: S
authors.initials: S
authors.lastname: Lyu
authors.forename: Y Y
authors.initials: YY
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Yang
authors.forename: H
authors.initials: H
authors.lastname: Geng
authors.forename: H
authors.initials: H
authors.lastname: Lin
authors.forename: S Y
authors.initials: SY
authors.lastname: Wang
authors.forename: R N
authors.initials: RN
authors.lastname: Xu
authors.forename: L F
authors.initials: LF
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Shi
authors.forename: F S
authors.initials: FS
authors.lastname: Wang
mesh_terms: D006509:Hepatitis B / Q000628:therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000628:therapy* / Q000821:virology; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology; D014470:Umbilical Cord / Q000166:cytology*